1. Home
  2. NBTX vs RANG Comparison

NBTX vs RANG Comparison

Compare NBTX & RANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NBTX
  • RANG
  • Stock Information
  • Founded
  • NBTX 2003
  • RANG 2024
  • Country
  • NBTX France
  • RANG United States
  • Employees
  • NBTX N/A
  • RANG N/A
  • Industry
  • NBTX Biotechnology: Pharmaceutical Preparations
  • RANG
  • Sector
  • NBTX Health Care
  • RANG
  • Exchange
  • NBTX Nasdaq
  • RANG Nasdaq
  • Market Cap
  • NBTX 178.7M
  • RANG 165.2M
  • IPO Year
  • NBTX 2020
  • RANG 2024
  • Fundamental
  • Price
  • NBTX $3.41
  • RANG $10.13
  • Analyst Decision
  • NBTX Strong Buy
  • RANG
  • Analyst Count
  • NBTX 1
  • RANG 0
  • Target Price
  • NBTX $8.00
  • RANG N/A
  • AVG Volume (30 Days)
  • NBTX 7.6K
  • RANG 15.6K
  • Earning Date
  • NBTX 04-02-2025
  • RANG 01-01-0001
  • Dividend Yield
  • NBTX N/A
  • RANG N/A
  • EPS Growth
  • NBTX N/A
  • RANG N/A
  • EPS
  • NBTX N/A
  • RANG N/A
  • Revenue
  • NBTX N/A
  • RANG N/A
  • Revenue This Year
  • NBTX N/A
  • RANG N/A
  • Revenue Next Year
  • NBTX $221.06
  • RANG N/A
  • P/E Ratio
  • NBTX N/A
  • RANG N/A
  • Revenue Growth
  • NBTX N/A
  • RANG N/A
  • 52 Week Low
  • NBTX $2.76
  • RANG $9.91
  • 52 Week High
  • NBTX $7.51
  • RANG $10.64
  • Technical
  • Relative Strength Index (RSI)
  • NBTX 52.75
  • RANG N/A
  • Support Level
  • NBTX $3.26
  • RANG N/A
  • Resistance Level
  • NBTX $3.65
  • RANG N/A
  • Average True Range (ATR)
  • NBTX 0.19
  • RANG 0.00
  • MACD
  • NBTX 0.02
  • RANG 0.00
  • Stochastic Oscillator
  • NBTX 35.00
  • RANG 0.00

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

About RANG Range Capital Acquisition Corp. Ordinary Shares

Range Capital Acquisition Corp is a blank check company.

Share on Social Networks: